Table 4.
Sensitivity, specificity and AUC values obtained using various cut-off values.
| Category | apoA2-ATQ/AT Cut-Off Value (μg/mL) |
Original Estimate | Bias-Adjusted Estimate *,1 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Se (%) | (95% CI) | Sp (%) | (95% CI) | AUC | (95% CI) | Se (%) | Sp (%) | AUC | ||
| PC (n = 41) |
≤35.0 | 51.2 | (35.1–67.1) | 98.8 | (98.4–99.1) | 0.903 | (0.851–0.955) | 51.3 | 98.8 | 0.889 |
| ≤40.0 | 61.0 | (44.5–75.8) | 96.5 | (95.9–97.0) | 61.5 | 96.5 | ||||
| ≤45.4 | 73.2 | (57.1–85.8) | 90.5 | (89.6–91.4) | 72.0 | 90.6 | ||||
| Resectable PC (n = 17) |
≤35.0 | 41.2 | (18.4–67.1) | 98.8 | (98.4–99.1) | 0.864 | (0.765–0.963) | 40.6 | 98.9 | 0.845 |
| ≤40.0 | 47.1 | (23.0–72.2) | 96.5 | (95.9–97.0) | 47.5 | 96.6 | ||||
| ≤45.4 | 64.7 | (38.3–85.8) | 90.5 | (89.6–91.4) | 61.0 | 90.6 | ||||
| Unresectable PC (n = 24) |
≤35.0 | 58.3 | (36.6–77.9) | 98.8 | (98.4–99.1) | 0.930 | (0.877–0.983) | 58.2 | 98.8 | 0.892 |
| ≤40.0 | 70.8 | (48.9–87.4) | 96.5 | (95.9–97.0) | 71.0 | 96.6 | ||||
| ≤45.4 | 79.2 | (57.8–92.9) | 90.5 | (89.6–91.4) | 79.0 | 90.7 | ||||
| PCL (n = 24) |
≤35.0 | 20.8 | (7.1–42.2) | 98.8 | (98.4–99.1) | 0.782 | (0.675–0.889) | 19.7 | 98.8 | 0.767 |
| ≤40.0 | 33.3 | (15.6–55.3) | 96.5 | (95.9–97.0) | 30.1 | 96.6 | ||||
| ≤45.4 | 58.3 | (36.6–77.9) | 90.5 | (89.6–91.4) | 49.6 | 90.9 | ||||
| CP (n = 13) |
≤35.0 | 53.8 | (25.1–80.8) | 98.8 | (98.4–99.1) | 0.871 | (0.722–1.000) | 51.3 | 98.9 | 0.863 |
| ≤40.0 | 69.2 | (38.6–90.9) | 96.5 | (95.9–97.0) | 65.7 | 96.7 | ||||
| ≤45.4 | 76.9 | (46.2–95.0) | 90.5 | (89.6–91.4) | 73.5 | 90.7 | ||||
A combination of subjects from the experimental prospective screening study and the cross-sectional study was used for this analysis. PC, pancreatic cancer; PCL, pancreatic cystic lesions; CP, chronic pancreatitis; Se, sensitivity; Sp, specificity; AUC, area under the ROC curve. *,1 The 0.632+ bootstrap method was used.